School of Medicine

Wayne State University School of Medicine

COMBI RX- The NIH sponsored study combining Copaxone® and Avonex® - Closed to Enrollment

This study is a 3 year multi-center study comparing the combined use of interferon beta-1a (Avonex ®) with glatiramer acetate (Copaxone®) in patients with Relapsing Remitting Multiple Sclerosis (RRMS). Patients will be randomly assigned to receive either: Avonex® and Copaxone®, Avonex® and placebo(dummy injection), or Copaxone® and placebo (dummy injection). Avonex is an intramuscular injection given once a week, Copaxone is an injection given under the skin daily. All patients enrolled in this study will take 8 injections a week.

Eligibility: Patients 18-60 years old with RRMS, who are able to walk at least 100 meters without aid or rest, and have had at least two relapses in the previous three years.

For more information visit: COMBIRX